Follow
Click to Follow pfizer_news
Pfizer Inc.
@pfizer_news
The official Twitter channel dedicated to media announcements & investor communications from Pfizer Inc. To see all of our Tweets, please follow .
Pfizer Inc.’s Tweets
Today along with , we announced the signing of a letter of intent with , a Cape Town-based, South African biopharmaceutical company, to manufacture the Pfizer-BioNTech COVID-19 Vaccine for distribution within the African Union:
Thomson Reuters CEO James C. Smith elected to Pfizer Board of Directors on.pfizer.com/1jn5Ov5
In order to realize the breakthroughs of the future, we’ve revolutionized how we work today. We're unlocking the pill to reveal Pfizer’s DNA: the power of science.
Today, we announced the start of a Phase 3 clinical study investigating our #Lymedisease vaccine candidate, being developed in partnership with .
Learn more about our research: on.pfizer.com/3PgVwlq
UPDATE: Earlier today, we announced preliminary data from our ongoing Phase 1/2 study with for a SARS-CoV-2 mRNA-based #vaccine candidate: on.pfizer.com/38poFqI $PFE #COVID19
Today’s announcement that the granted Fast Track designation for two of our leading #COVID19 #vaccine candidates signifies an important milestone in our efforts: on.pfizer.com/32bLZXH
Together with , we announced positive data on the use of our #Lyme disease vaccine candidate in children aged 5-17 years. Read more: on.pfizer.com/3LmaghI
read image description
ALT
Today with , we are excited to announce additional positive Phase 2 results, including booster response, for our Lyme disease #vaccine candidate.
Today, along with , we shared positive early data on our lead mRNA-based #vaccine candidate (BNT162b2) against #COVID19: on.pfizer.com/3gdH5wJ $PFE $BNTX
Today we entered into a definitive merger agreement under which we will acquire . Read More: investors.pfizer.com/investor-news/
BREAKING: Today, with , we submitted a request to US FDA to expand emergency use of our COVID-19 vaccine to adolescents 12 to 15 years of age.
Today, with , we released results from an in vitro study indicating sera from people immunized with the Pfizer-BioNTech #COVID19 vaccine can neutralize the SARS-CoV-2 U.K. strain. Learn more: on.pfizer.com/38Z7Cxx
Today with , we are proud to announce positive topline results from the pivotal trial of our #COVID19 vaccine in children 5-11 years of age. on.pfizer.com/2ZfSk55
Today with , we’re proud to announce that results from the Phase 2/3 study for the Pfizer-BioNTech #COVID19 Vaccine in children 5 through 11 years of age were published in The New England Journal of Medicine ().
Today we shared new data with demonstrating the stability of our #COVID19 vaccine when stored at -25°C to -15°C (-13°F to 5°F), temperatures more commonly found in pharmaceutical freezers and refrigerators. on.pfizer.com/2ZygXXr
Together with , we are pleased to announce encouraging antibody persistence data six months after the last dose of our #Lymedisease vaccine candidate in development for adults and children aged 5-65.
Learn more about our research: on.pfizer.com/3B24Tkm
Updated Phase 1/2 data for our investigational #hemophilia A treatment in partnership with were presented today at #ASH19. ICYMI: bwnews.pr/2P030NA #raredisease
Pfizer doses first patient using investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular dystrophy
on.pfizer.com/2qqQVn7
Today with , we announced plans to expand our agreement with the U.S. government to provide 500 million more doses of our #COVID19 vaccine to be distributed to countries around the world.
Learn more: on.pfizer.com/3ERg3Jg
We are pleased to share the publication of two studies related to our investigational vaccine for the prevention of respiratory syncytial virus (RSV), in The Journal of Infectious Diseases:
on.pfizer.com/3Lob0D8
on.pfizer.com/3LmnlYH
read image description
ALT
We’re pleased to share the filing acceptance of our 20-valent pneumococcal conjugate vaccine candidate (#20vPnC) in infants and children. on.pfizer.com/3CsLxpc
Today, the approved our once-daily oral treatment for adults with refractory moderate-to-severe #atopicdermatitis who have not responded to other systemic treatments or for whom these treatments are inadvisable. Learn more:
BREAKING: granted emergency use authorization of a booster dose of our #COVID19 vaccine w for individuals 65+, and 18+ through 64 within certain high risk groups. This is the first FDA EUA of a COVID-19 vaccine booster.
Learn more: on.pfizer.com/3hWvS7m
BREAKING: The Conditional Marketing Authorization in the EU for the Pfizer-BioNTech #COVID19 vaccine has been expanded to include adolescents 12 to 15 years old.
Proud to announce we’ve teamed up w/ to develop new #mhealth #tech for #Parkinsons #neuro on.pfizer.com/25N0F9U
Today, we announced preliminary preclinical data with for BNT162b2, our mRNA-based #vaccine candidate against #COVID19: on.pfizer.com/3hg6N4h $PFE $BNTX
We are pleased to share the and have accepted the filing applications for our investigational bispecific antibody treatment for people living with relapsed or refractory multiple myeloma (#RRMM). Learn more: on.pfizer.com/3SiOZK1 #MultipleMyeloma #MMSM
BREAKING: Our nasal spray for the acute treatment of #migraine received approval, offering a new treatment option. Learn more about this important milestone here: on.pfizer.com/3l6y9lp
BREAKING: Today, the Vaccines and Related Biological Committee (#VRBPAC) voted in support of approval for our vaccine candidate to help prevent RSV in infants through maternal immunization.
Read more: pfizer.com/news/press-rel
Our work continues and in just a few weeks, we will share new data on our medicines at the first ever virtual ASCO meeting. Learn more about our oncology portfolio #ASCO20: on.pfizer.com/3bpqOCv
Announced today: positive topline results from our Phase 3 trial in advanced #prostatecancer. We are proud to take this step toward potentially addressing unmet needs among this population. on.pfizer.com/3RzYJNR
Results from an in vitro study show sera from clinical trial participants who received the Pfizer-BioNTech COVID-19 vaccine effectively neutralized SARS-CoV-2 having 1 key mutation also found in 2 highly transmissible strains. Learn more: on.pfizer.com/2MMBSDd
BREAKING: The has approved our combination therapy for the treatment of metastatic castration-resistant #ProstateCancer (mCRPC) in adults with homologous recombination repair (HRR) gene mutations: bit.ly/3NDLUmT
read image description
ALT
Building on our leadership in #breastcancer innovation, today we announced a global collaboration w/ to develop a novel PROTAC® Protein Degrader. Learn more here: on.pfizer.com/2W04aP2
Pfizer announces CEO succession plan: Dr. Albert Bourla to succeed Ian Read as CEO, effective January 1, 2019 on.pfizer.com/2OWQdci $PFE
Today, with , we announced positive topline results in adolescents 12-15 years of age from the Phase 3 Pfizer-BioNTech #COVID19 vaccine study.
Today we announced positive top-line results from a Phase 3 study of our investigational treatment for patients 12 and older with moderate to severe atopic #dermatitis: on.pfizer.com/2Yvv90N
We're pleased to announce that our investigational treatment for relapsed or refractory #multiplemyeloma was granted U.S. FDA Breakthrough Therapy Designation. MM is an aggressive blood cancer with limited treatment options for these patients. Learn more: on.pfizer.com/3fwBgAg
We’re pleased to share that the European Commission has approved our #oncology supportive care #biosimilar in people living with certain types of #cancer. Find out more: on.pfizer.com/33ablFe
BREAKING: Today, we announced that the has approved our bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by #RSV in individuals 60 years and older. Read more: on.pfizer.com/3C33LwW
Today, along with we announced the signing of a letter of intent with Brazil biopharmaceutical company to manufacture the Pfizer-BioNTech COVID19 Vaccine for distribution across Latin America: on.pfizer.com/3kvao1R
Today, we announced positive top-line data from a Phase 3 study evaluating our investigational gene therapy for the treatment of adult males with moderately severe to severe #hemophiliaB.
Learn more about the study here: on.pfizer.com/3WNxJgX
We’re pleased to announce Phase 3 data in #prostatecancer to be presented at #GU18: on.pfizer.com/PROSPER
Today we announced the acquisition of , the maker of NURTEC® ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults. Read the announcement press release: on.pfizer.com/3RCnetH
BREAKING: The Vaccines and Related Biological Products Advisory Committee (#VRBPAC) voted in support of granting Emergency Use Authorization (EUA) for the Pfizer-BioNTech #COVID19 vaccine in children ages 5 to <12 years.
Learn more: on.pfizer.com/3Ee7eb2
The has accepted for review two NDAs for our investigational treatment for transthyretin amyloid cardiomyopathy, a #raredisease that affects the heart. Learn more: on.pfizer.com/2M9obK7
As SARS-CoV-2 continues to evolve, we are working w/ to understand potential long-term immunity afforded by our vaccine, whether there will be a need for booster shots, and any threat to protection by our vaccine from circulating or new variants of concern.
read image description
ALT
Updated topline analysis of 927 confirmed symptomatic cases of #COVID19 from the landmark Pfizer-BioNTech COVID-19 vaccine study showed high efficacy and favorable safety profile of the vaccine.
We’re pleased to share that the U.S. FDA has approved our first-line treatment for patients with metastatic #NSCLC with certain EGFR-activating mutations. on.pfizer.com/2N93Gfs
The has granted Fast Track designation for our investigational #genetherapy for the treatment of #Duchenne muscular dystrophy, signifying an important milestone for this community. Learn more: on.pfizer.com/33jCBBJ
Following an extensive discussion with President Trump, Ian Read announced that it will defer the company’s July 1 price increases to give the president an opportunity to work on his blueprint to strengthen the healthcare system and provide more access for patients.
We’re proud to announce that the US FDA has accepted our sNDA filing and granted Priority Review for our advanced #prostatecancer therapy. Read more: on.pfizer.com/2KMKK8w
Today, we announced the start of a Phase 3 trial evaluating our investigational vaccine candidate against respiratory syncytial virus (#RSV) in adults ages 60 years or older. on.pfizer.com/3tbjoNz
Today, with , we announced results from an in vitro study published in examining whether sera from individuals vaccinated with our #COVID19 vaccine neutralized SARS-CoV-2 with the South African variant spike protein. Learn more:
We received FDA Fast Track designation w/ for investigational non-opioid therapy for 2 #chronicpain types on.pfizer.com/2rW9PUI
We’re pleased to announce an expanded collaboration with as we continue our pursuit to unlock the power of #realworldevidence in #oncology to improve medicines development. on.pfizer.com/2mvYx9t
Sharing progress on the most recent research and development activities that reinforce the dedication behind our five-point plan to battle the #COVID19 pandemic: on.pfizer.com/39QtbgU
Today, the FDA approved our breakthrough therapy for relapsed/refractory Acute Lymphoblastic #Leukemia in adults on.pfizer.com/2x8hOhu
Today, with , we announced results from an in vitro study conducted with demonstrating sera from individuals vaccinated with our #COVID19 vaccine:
Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an investigational oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata pfizer.com/news/press-rel
NEWS: grants approval of a vaccine to help protect against pneumococcal disease in adults 18 years and older. More: on.pfizer.com/3iovksd
Pfizer To Build Cutting-Edge Sterile Injectable Facility In Michigan, Investing Nearly Half A Billion Dollars In U.S. Manufacturing, Creating More Than 450 Jobs on.pfizer.com/2mILLBj
Replying to
The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by FDA but has been authorized for emergency use to prevent COVID-19 in ages 12+. See Fact Sheet: cvdvaccine-us.com/recipients
We are proudly continuing our commitment to the #Duchenne muscular dystrophy community. Today, we announced the first participant was dosed in our Phase 3 investigational gene therapy trial for affected boys aged 4-7. on.pfizer.com/39apCUr
Today, we announced the initiation of four Phase 3 studies within our current pipeline of investigational vaccines. Learn more about the vaccine candidates: on.pfizer.com/3hODVSf
We are proud to announce that the has approved our treatment regimen for adults living with BRAF V600E-mutant metastatic #colorectalcancer who have received prior therapy. Learn more: on.pfizer.com/2RlMJ6z
Today, Pfizer pledged $100 million to the AMR Action Fund, a collaboration between more than 20 biopharma companies to help reinvigorate the antibiotic pipeline and fight #antimicrobialresistance. Get all the details: on.pfizer.com/2CeUR3X
read image description
ALT
We’re excited to announce positive Phase 2 data in alopecia areata presented as a late-breaker at #EADV2018. Learn more: on.pfizer.com/2xlUAG6
UPDATE: We have completed the transaction to combine our Upjohn business with @MylanNews to form : on.pfizer.com/3lCincT
$PFE $MYL $VTRS
Replying to
The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the FDA but has been authorized for emergency use to prevent COVID-19 in ages 12+. See Fact Sheet: cvdvaccine-us.com/recipients
Today we entered a collaboration with in the U.S. and Canada, with the goal of advancing care in #oncology and #womenshealth. Learn more: pfizer.com/news/press-rel
Today’s FDA approval marks an exciting breakthrough for young patients with ALK-positive #ALCL & addresses a significant unmet need in #bloodcancer. Learn more: on.pfizer.com/35F0Fzw
To further expand our commitment to #infectiousdisease, we announced an agreement under which Pfizer has acquired Amplyx Pharmacueticals, Inc. Learn more about this news & hear from Angela Lukin: on.pfizer.com/2R6rkAK
. today approved our therapy for moderately to severely active #ulcerativecolitis: on.pfizer.com/2sp3ssh
Today with , we announced the first results from any randomized, controlled #COVID19 vaccine booster trial. We look forward to sharing these data with regulatory agencies and submitting them for peer-reviewed publication. on.pfizer.com/3C6mYw8
As we continue to be led by the science, today we are providing an update on our comprehensive #COVID19 vaccine booster strategy in light of emerging data including data relating to the #DeltaVariant. on.pfizer.com/3ehkod9
Today, our RSV vaccine candidate programs took significant steps forward: accepted our application for maternal immunization, and has accepted our applications for older adults and maternal immunization. Learn more: on.pfizer.com/3lZD5bC
Today, the granted Breakthrough Therapy Designation for our vaccine to help prevent meningococcal group B disease in children ages 1-9. Read more: on.pfizer.com/2qYcWKv
We continuously innovate to bring treatments to underserved patient populations. Today, the approved an expanded indication for our medicine for a certain type of #metastaticBC to include the treatment of men based predominately on #realworlddata. on.pfizer.com/2I8nqRD
FDA grants Pfizer Breakthrough Therapy Designation for a next-generation vaccine intended to help prevent pneumococcal disease in adults aged 18 years and older. Learn more: on.pfizer.com/2MNlkW0
The 2020 #PrixGalien USA Award is a testament to professors Jeffery Kelly, PhD, and Evan Powers, PhD who helped develop our innovative treatment for ATTR-CM. #PfizerProud
read image description
ALT
NEWS: Pfizer has finalized an investment in – including terms on a potential medicine to treat multi-drug resistant infections in the hospital setting bit.ly/3x804Ck
read image description
ALT
Our Phase 3 CROWN trial in people with previously untreated ALK-positive #NSCLC met its primary endpoint. Read the announcement here: on.pfizer.com/3kau5LL #LCSM
In collaboration with , we’re proud to announce that the first participant was dosed in a phase 3 investigational gene therapy trial for patients with #hemophilia A. Learn more about the trial and our gene therapy efforts:
on.pfizer.com/2SBy3R0
Today we announced an agreement under which Pfizer will acquire Trillium Therapeutics, enhancing our Oncology pipeline with two potential next-generation IO therapies. Learn more here: on.pfizer.com/3jbtpau
Announced today: positive results from the Phase 3 trial of our #RSV maternal vaccine candidate. These data have shown that this vaccine candidate can help protect newborns against severe RSV-related respiratory illness immediately at birth. Learn more: on.pfizer.com/3SVBcI3
Today, we announced positive top-line data from a Phase 3 trial of our bivalent respiratory syncytial virus vaccine candidate (#RSVpreF) in older adults, bringing us one step closer to helping address the substantial burden of RSV disease. on.pfizer.com/3pGTC35
We’re proud to announce that the has approved our advanced #prostatecancer therapy to treat men with metastatic castration-sensitive prostate cancer. Learn more: investors.pfizer.com/investor-news/
Today, we announced the filing acceptance of our pentavalent meningococcal vaccine candidate (#MenABCWY) in adolescents. If approved, the vaccine could help simplify the meningococcal vaccination schedule.
Read more: on.pfizer.com/3WPYYHC
We’re pleased to share data for one of our proposed #biosimilar medicines at #ESMO17 #breastcancer on.pfizer.com/2vXqfjp
Today, with , we started an evaluation of the safety and immune response of a third dose of the Pfizer-BioNTech #COVID19 vaccine against circulating virus variants. Read the release: on.pfizer.com/3pTXgV1
CHMP has granted a positive opinion recommending approval of our & ’s #immunotherapy, for first-line maintenance treatment of certain patients with advanced #urothelialcancer. To read more: on.pfizer.com/3m7FlIf
The FDA granted Breakthrough Therapy designation for our investigational treatment for alopecia areata. Learn more: on.pfizer.com/2PHCPJd
We’re proud to announce that a new treatment for certain patients with the most common type of hereditary #breastcancer has been approved by the FDA on.pfizer.com/2CkV03J $PFE
